Copyright
©The Author(s) 2021.
World J Exp Med. Mar 20, 2021; 11(2): 17-29
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
Published online Mar 20, 2021. doi: 10.5493/wjem.v11.i2.17
n | Mean | SD | Mean rank | χ2 | df | P value | |
Pre-test | 8 | 21.88 | 2.17 | 5.81 | 38.875 | 5 | 0.000 |
Post-test 1 wk | 8 | 19.75 | 3.28 | 5.06 | |||
Post-test 1 mo | 8 | 18.25 | 3.24 | 3.94 | |||
Post-test 2 mo | 8 | 17.00 | 3.59 | 3.19 | |||
Post-test 4 mo | 8 | 14.75 | 3.69 | 1.94 | |||
Post-test 12 mo | 8 | 13.00 | 4.24 | 1.06 |
- Citation: Kabataş S, Civelek E, Kaplan N, Savrunlu EC, Sezen GB, Chasan M, Can H, Genç A, Akyuva Y, Boyalı O, Diren F, Karaoz E. Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World J Exp Med 2021; 11(2): 17-29
- URL: https://www.wjgnet.com/2220-315x/full/v11/i2/17.htm
- DOI: https://dx.doi.org/10.5493/wjem.v11.i2.17